Intrexon Buys Tools, Wins Partners
Intrexon’s acquisitions since mid-2014 have given it a shot at solving some high-profile challenges, and have attracted mainstream pharmaceutical partners.
You may also be interested in...
Synthetic biology offers opportunity across many industries, but the ultimate prize may be health care. The millions of dollars investors have poured into companies developing CAR-T cell therapies and gene editing technologies points to growing confidence in the power of gene manipulation to generate novel, approvable therapeutics, even if for now these are just the early steps toward creating fully synthetic organisms.
True to its word, Merck Serono is boosting its immune-oncology platform by signing an exclusive strategic collaboration and license agreement to develop and commercialize chimeric antigen receptor T-cell (CAR-T) cancer therapies with Intrexon for an upfront payment of $115m.
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.